September 10, 2025Cancer Research and TreatmentOpen Access

Real-World Efficacy and Safety of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma: Nationwide Retrospective Analysis of the Named Patient Program in Korea

View Full Paper

Ask AI

Bookmark

Authors

JYJun Ho YiSamsung Medical Center JLJae Hoon LeeYonsei University SJSunghoon JungChungnam National University

Discussion

Member takes

Implication

Retrospective analysis shows a 66.7% response rate in patients with relapsed or refractory multiple myeloma, suggesting teclistamab's effectiveness and manageable safety profile.

Key Points

Teclistamab resulted in a 66.7% overall response rate in patients with relapsed or refractory multiple myeloma.
Among the participants, 17 patients achieved a complete or deeper response, highlighting significant treatment efficacy.
A median progression-free survival of 14.1 months was observed, with a notable impact of R-ISS stage on outcomes.
Patient safety was maintained with manageable rates of cytokine release syndrome and infections, similar to findings from the MajesTEC-1 trial.

Cite This Study

Yi et al. (2025) studied this question.

synapsesocial.com/papers/68c23e02b210217d64790ad4 https://doi.org/10.4143/crt.2025.399

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows a 66.7% response rate in patients with relapsed or refractory multiple myeloma, suggesting teclistamab's effectiveness and manageable safety profile.

Real-World Efficacy and Safety of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma: Nationwide Retrospective Analysis of the Named Patient Program in Korea

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-World Efficacy and Safety of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma: Nationwide Retrospective Analysis of the Named Patient Program in Korea

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider